Hugh Cole - Aug 1, 2022 Form 4 Insider Report for Jounce Therapeutics, Inc. (JNCE)

Role
Chief Operating Officer
Signature
/s/ Caroline Gammill, Attorney-in-fact
Stock symbol
JNCE
Transactions as of
Aug 1, 2022
Transactions value $
$0
Form type
4
Date filed
8/3/2022, 08:29 PM
Previous filing
Jun 21, 2022
Next filing
Jan 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNCE Common Stock Award $0 +20K +18.74% $0.00 127K Aug 1, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNCE Stock Option (Right to Buy) Award $0 +40K $0.00 40K Aug 1, 2022 Common Stock 40K $2.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest quarterly in 16 equal installments following August 1, 2022.